• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure lands $150m term loan

February 8, 2018 By Sarah Faulkner

NovocureNovocure (NSDQ:NVCR) has inked a $150 million term loan agreement with Pharmakon Advisors’ investment fund, BioPharma Credit.

The St. Helier, N.J.-based company plans to set aside some of the new funds for working capital, as well as pay off its existing $100 million term loan debt.

“Novocure is a global oncology company with a proprietary platform technology, and we are pleased to further strengthen our cash position with non-dilutive capital,” Novocure’s chief finance executive, Wilco Groenhuysen, said in prepared remarks.

“This new credit facility provides us with the financial stability and flexibility to continue to execute our core strategies of driving commercial adoption of Optune and advancing our clinical pipeline.”

The company’s Optune system delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication.

Last week, Novocure touted an analysis published in JAMA Oncology showing that its Optune-temozolomide combination helped newly-diagnosed glioblastoma patients live longer without hurting their quality of life.

In a Phase III pivotal trial, researchers found that a higher proportion of patients treated with Optune and temozolomide reported stable or improved quality of life measures compared to those treated with just temozolomide.

Researchers assessed health-related quality of life by giving the study participants a questionnaire at the beginning of the trial and every three months after. Out of the 695 patients who participated in the study, 639 of them filled out the questionnaire.

Health-related quality of life was evaluated based on nine measures – global health status, physical, cognitive, role, social and emotional functioning, itchy skin, pain and weakness of legs.

More people treated with the company’s combination therapy reported stable or improved scores for global health status, pain, physical functioning and leg weakness compared to those treated with just temozolomide. For example, 57% of people in the Optune-temozolomide group reported stable or improved pain scores compared to 36% in the temozolomide arm.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Neurological, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: NovoCure

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS